Tsumura & co (4540):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Tsumura & co (4540) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10089
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tsumura & co (Tsumura) is a traditional pharmaceutical products company, which undertakes the manufacturing and sale of Kampo extract intermediates and granular Kampo formulations. Its product portfolio includes a range of prescription Kampo products, other pharmaceuticals, over-the-counter (OTC) formulations, Chinese crude drug pieces for decoction and other products. The company provides Kampo products for treating abdominal pain and flatulence, neurosis, insomnia, anorexia, gastritis, maldigestion, cough, bronchitis, bronchial asthma, oversensitivity to cold, menstrual irregularity, climacteric disturbance, leg pain, low back pain, numbness, dysuria, swelling (edema), acute gastroenteritis, common cold, coryza, shoulder stiffness, stomatitis, fermentative diarrhea, neurotic gastritis and other diseases. The company along with its subsidiaries operates in the US, China and Japan. Tsumura is headquartered in Minato-ku, Tokyo, Japan.

Tsumura & co (4540) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tsumura & co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Tsumura & co, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Tsumura & co, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Tsumura Forms Joint Venture with Ping An Insurance 10
Tsumura Plans to Form Joint Venture with Tianjin-based Drug Firm 11
Equity Offering 12
Tsumura Raises USD243 Million in Public Offering of Shares 12
Debt Offering 13
Tsumura to Raise USD134.3 Million in Public Offering of 0.23% Bonds Due 2024 13
Tsumura to Raise USD134.3 Million in Public Offering of 0.345% Bonds Due 2027 14
Tsumura & co – Key Competitors 15
Tsumura & co – Key Employees 16
Tsumura & co – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Tsumura & co, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tsumura & co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tsumura & co, Deals By Therapy Area, 2012 to YTD 2018 8
Tsumura & co, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Tsumura Forms Joint Venture with Ping An Insurance 10
Tsumura Plans to Form Joint Venture with Tianjin-based Drug Firm 11
Tsumura Raises USD243 Million in Public Offering of Shares 12
Tsumura to Raise USD134.3 Million in Public Offering of 0.23% Bonds Due 2024 13
Tsumura to Raise USD134.3 Million in Public Offering of 0.345% Bonds Due 2027 14
Tsumura & co, Key Competitors 15
Tsumura & co, Key Employees 16
Tsumura & co, Other Locations 17
Tsumura & co, Subsidiaries 17

List of Figures
Tsumura & co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tsumura & co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tsumura & co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Tsumura & co (4540):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Interleukin Genetics Inc (ILIU)-製薬・医療分野:企業M&A・提携分析
    Summary Interleukin Genetics Inc (Interleukin) is a molecular diagnostics company which develops and distributes genetic tests for the personalized health market. Its major genetic tests include ILUSTRA genetic risk test ; cardiovascular risk test; weight management genetic test; bone health genetic …
  • Brembo SpA:戦略・SWOT・企業財務分析
    Brembo SpA - Strategy, SWOT and Corporate Finance Report Summary Brembo SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Aviva Ltd.:企業の戦略・SWOT・財務分析
    Aviva Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aviva Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Under Armour Inc (UAA):企業の財務・戦略的SWOT分析
    Under Armour Inc (UAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Kirloskar Brothers Ltd (KIRLOSBROS):企業の財務・戦略的SWOT分析
    Kirloskar Brothers Ltd (KIRLOSBROS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析
    Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Pancontinental Oil & Gas NL (PCL):企業の財務・戦略的SWOT分析
    Summary Pancontinental Oil & Gas NL (Pancontinental) is an oil and gas exploration and production company. The company carries out acquisition, exploration and development of conventional oil and gas properties. The company offers projects such as Namibia Walvis Basin EL 0037, Kenya Lamu Basin L6, T …
  • Les Laboratoires Servier SAS:企業の戦略的SWOT分析
    Les Laboratoires Servier SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Grunenthal GmbH:企業の戦略的SWOT分析
    Grunenthal GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • ORBCOMM Inc (ORBC):企業の財務・戦略的SWOT分析
    ORBCOMM Inc (ORBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • KLA-Tencor Corporation:戦略・SWOT・企業財務分析
    KLA-Tencor Corporation - Strategy, SWOT and Corporate Finance Report Summary KLA-Tencor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • OBI Pharma Inc (4174):医療機器:M&Aディール及び事業提携情報
    Summary OBI Pharma Inc (OBI Pharma) is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer; and OBI-833, a …
  • Crown Bioscience Inc-医療機器分野:企業M&A・提携分析
    Summary Crown Bioscience Inc (Crown Bioscience) is a pharmaceutical company that provides drug discovery and development services. The company offers in vivo and in vitro research reagents. It offers preclinical contract research services in areas of oncology and metabolic disease. Crown Bioscience’ …
  • Ascena Retail Group Inc:企業の戦略的SWOT分析
    Ascena Retail Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Applied Medical Resources Corporation:企業の戦略的SWOT分析
    Applied Medical Resources Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Immunovia AB (IMMNOV):製薬・医療:M&Aディール及び事業提携情報
    Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease …
  • PT. Indonesia Power:企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Manhattan Construction Group:企業の戦略的SWOT分析
    Manhattan Construction Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Sojitz Corporation (2768)-石油・ガス分野:企業M&A・提携分析
    Summary Sojitz Corporation (Sojitz) is a diversified general trading group. The group through its subsidiaries and affiliates holds interest in machinery; energy and metals; chemicals and functional materials; and consumer lifestyle businesses. It distributes automobiles and aircraft; develops power …
  • Vodafone Group Plc:企業の戦略・SWOT・財務情報
    Vodafone Group Plc - Strategy, SWOT and Corporate Finance Report Summary Vodafone Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆